Pain medicine

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials

AnesthesiologyPublished Two phase 3 randomised controlled trials

Authors' conclusion

As compared with placebo, suzetrigine reduced moderate-to-severe acute pain over 48 h after abdominoplasty or bunionectomy. Pain reduction with suzetrigine was similar to that with hydrocodone bitartrate/acetaminophen. Suzetrigine was associated with adverse events that were mild to moderate in severity.

Study context

Population
Adults with moderate-to-severe acute pain (verbal categorical rating scale) and NRS ≥4 after abdominoplasty or bunionectomytwo trials · NRS ≥4 after abdominoplasty 1,118 · or bunionectomy 1,073
Comparison
Suzetrigine vs hydrocodone bitartrate/acetaminophen vs placebo for 48 h
Primary endpoint
Time-weighted sum of the pain intensity difference in NRS from 0 to 48 h (SPID48) vs placebo
Follow-up
0 to 48 h
Methodological detailsdouble-blind, placebo-controlled, active-controlled
  • Double-blind
  • Placebo-controlled
  • Active-controlled

Primary result

As reported in the abstract

SPID48
Suzetrigine vs PlaceboLeast squares mean difference (95% CI)P value
After abdominoplasty
48.4(33.6–63.1)
P < 0.0001
After bunionectomy
29.3(14.0–44.6)
P = 0.0002

Secondary outcomes

min

OutcomeSuzetriginePlaceboP value
Time to ≥2-point reduction in NRS from baseline vs placebo, abdominoplasty (key secondary)Nominal P119480P < 0.0001
Time to ≥2-point reduction in NRS from baseline vs placebo, bunionectomy (key secondary)Nominal P240480P = 0.0016

SPID48, suzetrigine vs hydrocodone bitartrate/acetaminophen (key secondary) · 0 to 48 h

Superiority of suzetrigine not achieved in either trial

Safety

Adverse events similar to those seen in postsurgical settings

Original publication

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. Published 21 March 2025. doi:10.1097/aln.0000000000005460

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.